This article is currently being researched and curated by our human editors and AI agents. Please check back shortly...
Back to Articles
SaaS Business Metrics
Why Your CRM Pipeline Lies About Deal Health
Disclaimer: Unless otherwise credited, all images on this page are for illustration purposes only and do not necessarily represent the actual products or services analysed. Our content is 100% data‑driven and based on verifiable research.
Learn more about our editorial standards →
💡 Related Business FAQs & Insights
Aggregated from enterprise communities, industry discussions, and our real-time cross-market analysis.
To provide the most accurate insights for Why Your CRM Pipeline Lies About Deal Health, we utilize programmatic analysis across millions of data points, including real-time market metrics, developer communities, and competitor databases to deliver unbiased, data-driven conclusions.
You are right, that would be a horrible deal for you.
Which is why only you decide if you want to convert at those bad terms. Not the issuer.
From the prospectus:
Each share of the Series L Preferred Stock will be convertible at any time, at your option, into 32.0513 shares of our common
stock (equivalent to an initial conversion price of approximately $31.20 per share of our common stock), [...]
The Series L Preferred Stock is not redeemable by us at any time.
[...]
if the closing price of ...
Which is why only you decide if you want to convert at those bad terms. Not the issuer.
From the prospectus:
Each share of the Series L Preferred Stock will be convertible at any time, at your option, into 32.0513 shares of our common
stock (equivalent to an initial conversion price of approximately $31.20 per share of our common stock), [...]
The Series L Preferred Stock is not redeemable by us at any time.
[...]
if the closing price of ...